PharmaCyte Biotech Accounts Payable

PharmaCyte Biotech posts a accounts payable of $270B as of April 2026. That compares with $400K in the prior-year period — up 67910542.2% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, PharmaCyte Biotech's accounts payable was $400K. The latest reading is $270B — a 67910542.2% year-over-year increase (period ending April 2026). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of PharmaCyte Biotech's financial statement story. At $270B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PMCB's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; PharmaCyte Biotech's other metric pages and overview cover the third.

Judging PharmaCyte Biotech against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in accounts payable easier to interpret. Start with $270B here, then scan peer and history charts to see if the gap is persistent.